Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
Clinical trial NCT01866319 · COMPLETED
Trial details
- NCT number
- NCT01866319
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-08-28
- Primary completion
- 2015-03-03
- Enrollment
- 834
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.